Health Condition 1: null- ASA 1 and 2 male and female between 18 to 70 years of age for upper limb surgeries below mid humerus. Health Condition 2: S50-S59- Injuries to the elbow and forearm Health Condition 3: S60-S69- Injuries to the wrist, hand and fingers
Conditions
Interventions
Intervention1: Study group D: Study group D will receive 29 ml Ropivacaine 75mg/ml with Dexmedetomidine 50 mcg made to 1 ml
Control Intervention1: Control group C: Control group C will receive 29 ml 7
Sponsors
Department of Anaesthesiology
Eligibility
Inclusion criteria
Inclusion criteria: ASA physical status 1 and 2, of either gender between 18 and 70 years of age for upper limb surgeries below mid humerus
Exclusion criteria
Exclusion criteria: morbid obesity, coagulopathy, uncontrolled diabetes mellitus, peripheral vascular disease, neurological disease, known allergy to local anaesthetics
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dexmedetomidine added to Ropivacaine prolongs the duration of analgesia, in hastening and prolonging sensory and motor block when compared to Ropivacaine alone in supraclavicular brachial plexus block for upper limb surgeriesTimepoint: Hemodynamic parameters,sensory and motor block, analgesia are assessed at 5, 10, 15, 20, 25, and 30 min and thereafter every 15 min for 1 hour till the block effect has resolved | — |
Secondary
| Measure | Time frame |
|---|---|
| Dexmedetomidine added to Ropivacaine is safer when compared to Ropivacaine alone in supraclavicular brachialplexus block for upper limb surgeriesTimepoint: Adverse effects are assessed at 5, 10, 15, 20, 25, and 30 min and thereafter every 15 min for 1 hour till the block effect has resolved | — |
Countries
India
Contacts
Public ContactDr Anna Mathew
Malankara Orthodox Syrian Church medicl college Kolenchery
Outcome results
None listed